research use only

Adapalene Retinoid Receptor agonist

Cat.No.S1276

Adapalene (CD-271) is a dual RAR and RXR agonist, used in the treatment of acne.
Jump to

Quality Control

Batch: Purity: 99.85%
99.85

Solubility

In vitro
Batch:

DMSO : 17 mg/mL (41.21 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 412.52 Formula

C28H28O3

Storage (From the date of receipt)
CAS No. 106685-40-9 Download SDF Storage of Stock Solutions

Synonyms CD-271 SMILES COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
RARγ
RARβ
RXR
In vitro
Adapalene binds to retinoic acid receptors found predominantly in the terminal differentiation zone of epidermis and is more active than tretinoin in modulating cellular differentiation. This compound shows greatest affinity for the subtype PARγ, found predominantly in the epidermis. It is more active than indomethacin, betamethasone valerate, tretinoin, isotretinoin or etretinate in inhibiting lipoxygease activity, but it has little activity against cyclo-oxygenase. This chemical time- and dose-dependently suppresses DNA synthesis and induces apoptosis in Colon carcinoma cell lines CC-531, HT-29 and LOVO as well as human foreskin fibroblasts. It shows significantly more effective antiproliferative and proapoptotic effects than 9-cis-retinoic acid (CRA), showing remarkable effects even at 10 μM. This compound disrupts DeltaPsi(m) and induces caspase-3 activity in responsive tumor cells.
In vivo
Adapalene produces a dose-related reduction in the number of epidermal comedones and an increase in comedo profile and epidermal thickness in the rhino mice. This compound results in a decreased expression of TLR-2 and IL-10 in explants of normal skin and explants of acne. It can modulate the epidermal immune system by increasing the CD1d expression and by decreasing the IL-10 expression by keratinocytes, and these modulations can increase the interactions between dendritic cells and T lymphocytes and could strengthen the antimicrobial activity against Propionibacterium acnes.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-29)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07524946 RECRUITING
Acne Vulgaris
Bausch Health Americas, Inc.
2026-04-01 PHASE4
NCT07421804 NOT_YET_RECRUITING
Acne Vulgaris
Assiut University
2026-04
NCT07673094 NOT_YET_RECRUITING
Acne Vulgaris
Khyber Teaching Hospital
2026-08-15 EARLY_PHASE1
NCT07805655 RECRUITING
Acne Vulgaris
Jeisys Medical Inc
2026-09-15
NCT07473895 NOT_YET_RECRUITING
Acne Vulgaris
Assiut University
2026-04 PHASE2
NCT07016360 RECRUITING
Viral Warts
Khyber Teaching Hospital
2025-09-15 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.